| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Jane A. McKeating | Q19561490 |
| David N. Frick | Q55098168 | ||
| P2093 | author name string | Stanley M Lemon | |
| Thomas Pietschmann | |||
| Phillip A Furman | |||
| Jeffrey S Glenn | |||
| Julian Symons | |||
| Timothy L Tellinghuisen | |||
| P2860 | cites work | Robust hepatitis C virus infection in vitro | Q27470013 |
| P433 | issue | 1 | |
| P304 | page(s) | 79-92 | |
| P577 | publication date | 2010-04-01 | |
| P1433 | published in | Antiviral Research | Q4775352 |
| P1476 | title | Development of novel therapies for hepatitis C. | |
| P478 | volume | 86 |
| Q44484475 | A combined proteomics and computational approach provides a better understanding of HCV-induced liver disease. |
| Q39158465 | ACH-806, an NS4A antagonist, inhibits hepatitis C virus replication by altering the composition of viral replication complexes |
| Q28743482 | An integrated transcriptomic and meta-analysis of hepatoma cells reveals factors that influence susceptibility to HCV infection |
| Q39158546 | Antiviral activity of Bacillus sp. isolated from the marine sponge Petromica citrina against bovine viral diarrhea virus, a surrogate model of the hepatitis C virus |
| Q35806182 | Characterization of resistance to the nonnucleoside NS5B inhibitor filibuvir in hepatitis C virus-infected patients |
| Q26998630 | Chutes and ladders in hepatitis C nucleoside drug development |
| Q34023851 | Drugs for Hepatitis C: Unlocking a New Mechanism of Action |
| Q37682499 | How hepatitis C virus invades hepatocytes: the mystery of viral entry |
| Q56762771 | IDX-184 is a superior HCV direct-acting antiviral drug: a QSAR study |
| Q36607790 | Identification and analysis of inhibitors targeting the hepatitis C virus NS3 helicase |
| Q27023055 | Innate immune responses in hepatitis C virus infection |
| Q35261158 | Last stop before exit - hepatitis C assembly and release as antiviral drug targets |
| Q28478310 | Mathematical model of viral kinetics in vitro estimates the number of E2-CD81 complexes necessary for hepatitis C virus entry |
| Q28481438 | Metabolism of phosphatidylinositol 4-kinase IIIα-dependent PI4P Is subverted by HCV and is targeted by a 4-anilino quinazoline with antiviral activity |
| Q42988260 | Molecular modeling comparison of the performance of NS5b polymerase inhibitor (PSI-7977) on prevalent HCV genotypes |
| Q35233150 | Prohibitin is overexpressed in Huh-7-HCV and Huh-7.5-HCV cells harboring in vitro transcribed full-length hepatitis C virus RNA. |
| Q42731526 | Prospects for personalizing antiviral therapy for hepatitis C virus with pharmacogenetics |
| Q39202816 | Psammaplin A inhibits hepatitis C virus NS3 helicase. |
| Q33815550 | Ribavirin-induced anemia in hepatitis C virus patients undergoing combination therapy |
| Q47335897 | Screening HCV genotype-specific epitope peptides based on conserved sequence analysis and B cell epitope prediction in HCV E2 region. |
| Q43048075 | Single and combined IL28B, ITPA and SLC28A3 host genetic markers modulating response to anti-hepatitis C therapy |
| Q34475801 | Structural and molecular basis of interaction of HCV non-structural protein 5A with human casein kinase 1α and PKR. |
| Q38849917 | Structure-activity relationship studies on quinoxalin-2(1H)-one derivatives containing thiazol-2-amine against hepatitis C virus leading to the discovery of BH6870. |
| Q39184615 | Synthesis and evaluation of non-dimeric HCV NS5A inhibitors |
| Q37824811 | Targeting cell entry of enveloped viruses as an antiviral strategy. |
| Q27682272 | The crystal structure of NS5A domain 1 from genotype 1a reveals new clues to the mechanism of action for dimeric HCV inhibitors |
| Q37699395 | Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. |
| Q40055099 | Zika viral polymerase inhibition using anti-HCV drugs both in market and under clinical trials |
Search more.